 |
|
|
| |
Glecaprevir/pibrentasvir & sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an
NS5A inhibitor containing antiviral regimen
|
| |
| |
EASL 2022 June 22-26 London
Edward J. Gane1, Bridget Faire2, Sherine Helmy3, James Freeman4. 1University of Auckland, Grafton Campus, Liver Unit, Auckland, New Zealand; 2New Zealand Liver Transplant Unit-Ward 71, Auckland, New Zealand; 3Pharco Corporation, Cairo, Egypt; 4GP2U, Australia
|
| |
|
|
|
|
|
